---
document_datetime: 2025-12-04 12:02:51
document_pages: 11
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/dengvaxia-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: dengvaxia-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 5.6667171
conversion_datetime: 2025-12-31 03:39:24.358493
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

<!-- image -->

| Application number   | Scope                                                                                                                                         | Opinion/ Notification 1 issued on product   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------|---------------------------------------------|----------------------------------|-----------|
| T/0033               | Transfer of Marketing Authorisation                                                                                                           | 27/11/2024                                  | 12/12/2024                                  | SmPC, Labelling and PL           |           |
| II/0032              | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority | 28/11/2024                                  | n/a                                         |                                  |           |

Dengvaxia Procedural steps taken and scientific information after the authorisation Application number Scope Commission Decision Issued 2  / amended Product Information affected 3 Summary T/0033 Transfer of Marketing Authorisation 12/12/2024 SmPC, Labelling and PL II/0032 C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority n/a Medicinal product no longer authorised

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

| II/0031   | Submission of final study report of DNG15, listed in the RMP as category 3. DNG15 was a prospective, multinational, non-interventional, observational study aiming to assess the risk of AEs associated with CYD dengue vaccine in the real-world immunization setting. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                         | 05/09/2024    | n/a        | Not applicable. authorised   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|------------|------------------------------|
| II/0030   | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                 | 18/07/2024    | n/a        | longer                       |
| II/0029   | Submission of the final report from study CYD69 listed as a category 3 study in the RMP. This is an Observational study: Effectiveness of the tetravalent dengue vaccine, CYD-TDV (DENGVAXIA) in the Philippines. This procedure fulfils post-authorisation commitment MEA 005 for Dengvaxia. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority Medicinal product | 27/06/2024 no | n/a        |                              |
| N/0028    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                              | 20/12/2023    | 12/12/2024 | PL                           |

<div style=\"page-break-after: always\"></div>

| R/0027              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                 | 22/06/2023   | 11/08/2023   | SmPC and PL   | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Dengvaxia in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. authorised   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10740 /202212 | Periodic Safety Update EU Single assessment - dengue tetravalent vaccine (live, attenuated) [Chimeric yellow fever dengue virus serotype 1 (live, attenuated) / Chimeric yellow fever dengue virus serotype 2 (live, attenuated) / Chimeric yellow fever dengue virus serotype 3 (live, attenuated) / Chimeric yellow fever dengue virus serotype 4 (live, attenuated)] | 06/07/2023   | n/a          | longer        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                    |
| IB/0026             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                           | 24/03/2023   | n/a no       |               |                                                                                                                                                                                                                                                                                      |
| IG/1559             | B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - Device with CE marking product                                                                                                                                                                             | 24/10/2022   | n/a          |               |                                                                                                                                                                                                                                                                                      |
| IB/0023             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation Medicinal                                                                                                                                                                                                                 | 13/07/2022   | n/a          |               |                                                                                                                                                                                                                                                                                      |
| PSUSA/10740 /202112 | Periodic Safety Update EU Single assessment - dengue tetravalent vaccine (live, attenuated) [Chimeric yellow fever dengue virus serotype 1 (live, attenuated) / Chimeric yellow fever dengue virus                                                                                                                                                                      | 07/07/2022   | n/a          |               | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                     | serotype 2 (live, attenuated) / Chimeric yellow fever dengue virus serotype 3 (live, attenuated) / Chimeric yellow fever dengue virus serotype 4 (live, attenuated)]                                                                                                                                                                                                                                                                                                        |            |               |             | authorised                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0022             | B.II.c.1.z - Change in the specification parameters and/or limits of an excipient - Other variation                                                                                                                                                                                                                                                                                                                                                                         | 21/06/2022 | n/a           |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| PSUSA/10740 /202106 | Periodic Safety Update EU Single assessment - dengue tetravalent vaccine (live, attenuated) [Chimeric yellow fever dengue virus serotype 1 (live, attenuated) / Chimeric yellow fever dengue virus serotype 2 (live, attenuated) / Chimeric yellow fever dengue virus serotype 3 (live, attenuated) / Chimeric yellow fever dengue virus serotype 4 (live, attenuated)]                                                                                                     | 13/01/2022 | n/a           | longer      | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| II/0013             | Update of sections 4.2 and 5.1 of the SmPC based on final results from study CYD65, listed as a category 3 study in the RMP; this is a Phase II, observer-blind, placebo-controlled trial in order to assess Immunogenicity and Safety of Tetravalent Dengue Vaccine Given in 1-, 2-, or 3-Dose Schedules Followed by a Single Booster. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data Medicinal product | 11/11/2021 | 09/12/2021 no | SmPC and PL | Results of study CYD65 showed no or modest transient increase of neutralizing Ab titers after the booster in dengue immune subjects. Why there is a lack of/limited booster effect with Dengvaxia remains not understood in terms of mechanisms and clinical implications. In the absence of immune correlates of protection, whether the absence or modest increases in Ab titers, plasmablasts, and memory B cells, do not translate or could translate in protection against dengue disease, during the first year post-boost or during a longer period, is not known. It was thus considered that the added value and timing for booster dose(s) have not been established. This paragraph was added to the Posology Section of the SmPC: |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | no         | longer                 | 'The added value of and appropriate timing for booster dose(s) have not been established. Current available data are included in section 5.1.' Cross-referred to the following text in Section 5.1: 'The effect of a booster dose was assessed in subjects 9-50 years living in endemic areas after a 3-dose schedule (studies CYD63, CYD64, CYD65). No or modest transient increase of neutralizing Ab titers was observed after the boost. The booster effect was variable across serotypes and studies. Why there is a lack/limited booster effect with Dengvaxia remains not understood in terms of mechanisms and clinical implications.' For more information, please refer to the Summary of authorised   |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0012 | Extension of indication to include paediatric population from 6 years of age for Dengvaxia; as a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC and sections 1, 2 and 4 of the Package Leaflet are updated. Furthermore, the MAH takes the opportunity to add an instruction for the installation of the needle in the SmPC and the Package Leaflet of the single-dose presentation. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one Medicinal product | 11/11/2021 | 09/12/2021 SmPC and PL | Product Characteristics. Please refer to Scientific Discussion 'Dengvaxia -H-C- 004171-II-0012'.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| II/0011 | Update of the PI impacting the Therapeutic                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 11/11/2021 | 09/12/2021 SmPC and PL | Please refer to Scientific Discussion 'Dengvaxia -H-C-                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                     | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                    |            |        | study CYD66. For more information, please refer to the Summary of Product Characteristics.   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|--------|----------------------------------------------------------------------------------------------|
| IB/0020             | B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                                                                                                                                                                                                                                  | 12/11/2021 | n/a    | authorised                                                                                   |
| PSUSA/10740 /202012 | Periodic Safety Update EU Single assessment - dengue tetravalent vaccine (live, attenuated) [Chimeric yellow fever dengue virus serotype 1 (live, attenuated) / Chimeric yellow fever dengue virus serotype 2 (live, attenuated) / Chimeric yellow fever dengue virus serotype 3 (live, attenuated) / Chimeric yellow fever dengue virus serotype 4 (live, attenuated)]                                                                                                                                              | 08/07/2021 | n/a no | PRAC Recommendation - maintenance longer                                                     |
| II/0018             | Submission of the final report from study DNG10042, listed as a category 3 study in the RMP. This report summarises the findings on the dengue vaccine (Dengvaxia) effectiveness against virologically confirmed symptomatic infection, carried out after the mass vaccination program conducted by the Brazilian state of Paran√° from 2016 to 2018. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority Medicinal product | 10/06/2021 | n/a    |                                                                                              |
| PSUSA/10740 /202006 | Periodic Safety Update EU Single assessment - dengue tetravalent vaccine (live, attenuated)                                                                                                                                                                                                                                                                                                                                                                                                                          | 14/01/2021 | n/a    | PRAC Recommendation - maintenance                                                            |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                     | [Chimeric yellow fever dengue virus serotype 1 (live, attenuated) / Chimeric yellow fever dengue virus serotype 2 (live, attenuated) / Chimeric yellow fever dengue virus serotype 3 (live, attenuated) / Chimeric yellow fever dengue virus serotype 4 (live, attenuated)]                                                                                                                                                                                         |            |            |                        | authorised                        |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| IB/0015             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                                                                                                                              | 20/11/2020 | n/a        | longer                 |                                   |
| PSUSA/10740 /201912 | Periodic Safety Update EU Single assessment - dengue tetravalent vaccine (live, attenuated) [Chimeric yellow fever dengue virus serotype 1 (live, attenuated) / Chimeric yellow fever dengue virus serotype 2 (live, attenuated) / Chimeric yellow fever dengue virus serotype 3 (live, attenuated) / Chimeric yellow fever dengue virus serotype 4 (live, attenuated)] product                                                                                     | 09/07/2020 | n/a no     |                        | PRAC Recommendation - maintenance |
| IB/0009/G           | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits B.II.d.1.z - Change in the specification parameters Medicinal | 23/04/2020 | 17/09/2020 | SmPC, Labelling and PL |                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | and/or limits of the finished product - Other variation B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State longer   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0007/G | This was an application for a group of variations. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority 13/02/2020 n/a product no                                                                                                                                                                                                          |
| IB/0006/G | This was an application for a group of variations. B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol 13/02/2020 n/a Medicinal                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| PSUSA/10740 /201906   | Periodic Safety Update EU Single assessment - dengue tetravalent vaccine (live, attenuated) [Chimeric yellow fever dengue virus serotype 1 (live,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 16/01/2020    | n/a                                                | PRAC Recommendation - maintenance   |
|-----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|----------------------------------------------------|-------------------------------------|
| II/0003/G             | attenuated) / Chimeric yellow fever dengue virus serotype 2 (live, attenuated) / Chimeric yellow fever dengue virus serotype 3 (live, attenuated) / Chimeric yellow fever dengue virus serotype 4 (live, attenuated)] This was an application for a group of variations. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                   | 19/09/2019 no | 17/09/2020 SmPC, Annex II, Labelling and PL longer | authorised                          |
| IA/0004/G             | This was an application for a group of variations. B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.II.c.1.c - Change in the specification parameters and/or limits of an excipient - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph Medicinal product | 16/05/2019    | n/a                                                |                                     |

<div style=\"page-break-after: always\"></div>

<!-- image -->